Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGCTSE:CXFNASDAQ:MENASDAQ:NEPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGCCanopy Growth$1.48-3.3%$1.38$0.77▼$8.65$272.12M0.756.03 million shs5.12 million shsCXFCI Canadian Convertible Bond ETF CommonC$10.21+0.1%C$9.99C$9.56▼C$10.57C$51.61MN/A4,442 shs500 shsME23andMe$0.50-35.3%$0.50$0.53▼$10.81$13.36M1.191.39 million shs29.28 million shsNEPTNeptune Wellness Solutions$0.39$0.19▼$28.00$906K2.19462,687 shs2.25 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGCCanopy Growth-3.27%-12.94%+4.96%+34.55%-80.50%CXFCI Canadian Convertible Bond ETF Common+0.10%+0.29%+2.10%+2.82%+5.04%ME23andMe0.00%0.00%0.00%-74.06%-93.96%NEPTNeptune Wellness Solutions0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGCCanopy Growth2.5742 of 5 stars2.52.00.00.03.50.01.3CXFCI Canadian Convertible Bond ETF CommonN/AN/AN/AN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGCCanopy Growth 1.00Sell$2.0035.14% UpsideCXFCI Canadian Convertible Bond ETF Common 0.00N/AN/AN/AME23andMe 1.00SellN/AN/ANEPTNeptune Wellness Solutions 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NEPT, CGC, CXF, and ME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/30/2025CGCCanopy GrowthPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderweight ➝ Underweight3/22/2025ME23andMeWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGCCanopy Growth$269.00M1.01N/AN/A$2.72 per share0.54CXFCI Canadian Convertible Bond ETF CommonN/AN/AN/AN/AN/AN/AME23andMe$208.78M0.06$0.54 per share0.93$2.34 per share0.21NEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGCCanopy Growth-$487.23M-$4.04N/AN/AN/A-156.98%-56.52%-24.18%8/8/2025 (Estimated)CXFCI Canadian Convertible Bond ETF CommonN/AN/A0.00∞N/AN/AN/AN/AN/AME23andMe-$666.70M-$15.45N/A∞N/A-183.39%-170.07%-62.13%N/ANEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%N/ALatest NEPT, CGC, CXF, and ME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/30/2025Q4 2025CGCCanopy Growth-$0.28-$0.94-$0.66-$1.00$71.84 million$45.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGCCanopy GrowthN/AN/AN/AN/AN/ACXFCI Canadian Convertible Bond ETF CommonC$0.484.70%N/AN/AN/AME23andMeN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGCCanopy Growth0.743.522.58CXFCI Canadian Convertible Bond ETF CommonN/AN/AN/AME23andMeN/A1.050.91NEPTNeptune Wellness SolutionsN/A0.230.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGCCanopy Growth3.33%CXFCI Canadian Convertible Bond ETF CommonN/AME23andMe36.10%NEPTNeptune Wellness Solutions14.44%Insider OwnershipCompanyInsider OwnershipCGCCanopy Growth1.30%CXFCI Canadian Convertible Bond ETF CommonN/AME23andMe26.32%NEPTNeptune Wellness Solutions5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGCCanopy Growth3,150183.87 million153.39 millionOptionableCXFCI Canadian Convertible Bond ETF Common905.05 millionN/ANot OptionableME23andMe77026.83 million19.77 millionNot OptionableNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionableNEPT, CGC, CXF, and ME HeadlinesRecent News About These Companiest20 world cup 2020 teamsDecember 28, 2024 | bweducation.businessworld.inNeptune Wellness Solutions Inc. (NEPTF)November 27, 2024 | finance.yahoo.comThree Breakthrough Strategies To Revolutionize Pain Relief And WellnessNovember 7, 2024 | forbes.comThe Aesthetic Experience introduces AE WellnessNovember 7, 2024 | koin.comNeptune homeless camp down to 13 people as deadline to shut it down is nearly hereOctober 18, 2024 | app.comThe Next Era of Lenovo Neptune Water Cooling Arrives to Efficiently Power NVIDIA Blackwell Platform and AI at Every ScaleOctober 15, 2024 | valdostadailytimes.comOpen Letter to Dominican President Luis Abinader: Stop Deportations Now!October 12, 2024 | counterpunch.org2024 Wellness Olympia Results & Prize Money — Isabelle Nunes Wins 1st TitleOctober 12, 2024 | fitnessvolt.comKroger Wellness Festival canceled, products will go to people impacted by HeleneSeptember 28, 2024 | local12.comRestore Hyper Wellness and MECOTEC Announce Strategic Partnership in Cryotherapy SolutionsSeptember 24, 2024 | tmcnet.comCapitol Wellness Solutions opens new medical marijuana dispensary in Baton RougeSeptember 21, 2024 | yahoo.comCapitol Wellness Solutions opened a new medical marijuana dispensary, for the first time in LouisianaSeptember 21, 2024 | msn.comGiant space balloon ‘Spaceship Neptune-Excelsior’ completes 2nd test flight in TitusvilleSeptember 19, 2024 | clickorlando.comSpace Perspective's Spaceship Neptune capsule lifts off from ship on test flightSeptember 16, 2024 | floridatoday.comNeptune Beach, FL Weather ConditionsAugust 30, 2024 | wunderground.comHigh-tech wizardry and old-fashioned care will grow pot indoors at Neptune's GardenAugust 30, 2024 | app.comYour Daily Horoscope: Sunday, August 25, 2024August 25, 2024 | msn.comExploring Alternative Wellness Options for Stress Management & RelaxationAugust 25, 2024 | spacecoastdaily.comSunrise Total Mind Wellness closing its doors in New BraunfelsAugust 18, 2024 | herald-zeitung.comNeptune Medical raises $97M for surgical robotics, spins out Jupiter EndovascularAugust 16, 2024 | therobotreport.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingTop 5 Stock Buys for June: AI Picks That Aren’t NVIDIABy Thomas Hughes | May 29, 2025View Top 5 Stock Buys for June: AI Picks That Aren’t NVIDIAConstellation Energy and Meta Strike Nuclear Deal, Shares WhipsawBy Leo Miller | June 4, 2025View Constellation Energy and Meta Strike Nuclear Deal, Shares WhipsawNEPT, CGC, CXF, and ME Company DescriptionsCanopy Growth NASDAQ:CGC$1.48 -0.05 (-3.27%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.48 0.00 (-0.34%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.CI Canadian Convertible Bond ETF Common TSE:CXFC$10.21 +0.01 (+0.10%) As of 06/13/2025 03:56 PM EasternChimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.23andMe NASDAQ:ME$0.50 -0.27 (-35.32%) Closing price 03/28/2025Extended Trading$0.50 0.00 (0.00%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.Neptune Wellness Solutions NASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
